VINCREX Drug Patent Profile
✉ Email this page to a colleague
When do Vincrex patents expire, and when can generic versions of Vincrex launch?
Vincrex is a drug marketed by Bristol Myers Squibb and is included in one NDA.
The generic ingredient in VINCREX is vincristine sulfate. There are thirteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the vincristine sulfate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VINCREX?
- What are the global sales for VINCREX?
- What is Average Wholesale Price for VINCREX?
Summary for VINCREX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 42 |
| Clinical Trials: | 87 |
| Patent Applications: | 4,216 |
| DailyMed Link: | VINCREX at DailyMed |
Recent Clinical Trials for VINCREX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Yazeed Sawalha | Phase 1 |
| City of Hope Medical Center | Phase 1 |
| AIDS Malignancy Consortium | Early Phase 1 |
US Patents and Regulatory Information for VINCREX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | VINCREX | vincristine sulfate | INJECTABLE;INJECTION | 070867-001 | Jul 12, 1988 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
